The list of approvals is constantly expanding towards more and more cancer types and therapeutic antibodies, which reflects the interest in PD-1/PD-L1 blockade and its prospects for clinical use (Cancer Research Institute, FDA Approval Timeline of Active Immunotherapies, www.cancerresearch.org, 3 October 2021). The gene discussed is CD274; the disease is cancer.